Clinical utility of elevated tumor markers in patients with disseminated appendiceal malignancies treated by cytoreductive surgery and HIPEC

European Journal of Surgical Oncology

Volumn 36, Issue 8, 2010, Pages 772-776

  Ross, A ^a   Sardi, A ^a   Nieroda, C ^a   Merriman, B ^b   Gushchin, V ^a  

^a MERCY MEDICAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Appendiceal malignancy; Cytoreductive surgery; HIPEC; Tumor markers

Indexed keywords

CA 125 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; MITOMYCIN C; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADULT; AGED; APPENDIX CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CYTOREDUCTIVE SURGERY; DISSEMINATED CANCER; FEMALE; FOLLOW UP; HUMAN; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PEITONEUM CARCINOMATOSIS; PERITONEUM CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; ADJUVANT CHEMOTHERAPY; APPENDIX TUMOR; BLOOD; EPIDEMIOLOGY; HYPERTHERMIC THERAPY; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; PERITONEUM TUMOR; PREDICTION AND FORECASTING; REGIONAL PERFUSION; SECRETION; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APPENDICEAL NEOPLASMS; CA-125 ANTIGEN; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHEMOTHERAPY, ADJUVANT; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; CONFOUNDING FACTORS (EPIDEMIOLOGY); FEMALE; HUMANS; HYPERTHERMIA, INDUCED; MALE; MIDDLE AGED; PATIENT SELECTION; PERITONEAL NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77954908748     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2010.05.024     Document Type: Article

References (14)

1. R.M. Smeenk, M.L.F. van Velthuysen, V.J. Verwaal, and F.A.N. Zoetmulder Appendiceal neoplasms and pseudomyxoma peritonei: a population based study Eur J Surg Oncol (EJSO) 34 2008 196 201
2. B.M. Ronnett, C.M. Zahn, and R.J. Kurman Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to "pseudomyxoma peritonei" Am J Surg Pathol 19 1995 1390 1408
3. B.W. Loggie, R.A. Fleming, and R.P. McQuellon Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of gastrointestinal origin Am Surg 66 2000 561 568
4. P.H. Sugarbaker New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol 7 2006 69 76
5. D. Baratti, S. Kusamura, and D. Nonaka Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) Ann Surg Oncol 15 2008 526 534
6. J.H. Stewart, P. Shen, and G.B. Russell Appendiceal neoplasms with peritoneal dissemination: outcomes after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy Ann Surg Oncol 13 2006 624 634
7. P.H. Sugarbaker, D. Chang, and P. Koslowe Prognostic features for peritoneal carcinomatosis in colorectal and appendiceal cancer patients when treated by cytoreductive surgery and intraperitoneal chemotherapy Cancer Treat Res 81 1996 89 104
8. Y. Fong, J. Fortner, and R.L. Sun Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases Ann Surg 230 1999 309 318
9. C.P. Carmignani, R. Hampton, and C.E. Sugarbaker Utility of CEA and CA 19-9 tumor markers in diagnosis and prognostic assessment of mucinous epithelial cancers of the appendix J Surg Oncol 87 2004 162 166
10. F. Alexander-Sefre, K. Chandrakumaran, and S. Banerjee Elevated tumour markers prior to complete tumour removal in patients with pseudomyxoma peritonei predict early recurrence Colorectal Dis 7 2005 382 386
11. S. van Ruth, A.A. Hart, and J.M. Bonfrer Prognostic value of baseline and serial carcinoembryonic antigen and carbohydrate antigen 19.9 measurements in patients with pseudomyxoma peritonei treated with cytoreduction and hyperthermic intraperitoneal chemotherapy Ann Surg Oncol 9 2002 961 967
12. R.L. Harmon, and P.H. Sugarbaker Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer Int Semin Surg Oncol 2 2005 3
13. F. Ghaemmaghami, Z.M. Karimi, and B. Hamedi High levels of CA 125 (over 1,000 IU/ml) in patients with gynecologic disease and no malignant conditions: three cases and literature review Arch Gynecol Obstet 276 2007 559 561
14. O. Glehen, F. Mohamed, and P.H. Sugarbaker Incomplete cytoreduction in 174 patients with peritoneal carcinomatosis from appendiceal malignancy Ann Surg 240 2004 278 285